Copay help by condition · Cancer and blood cancer · read 2026-11-08
Renal Cell Carcinoma (RCC): which charitable copay funds are open
1 fund for Renal Cell Carcinoma says it is open right now, of the 4 we hold (read 2026-11-08).
Open: Renal Cell Carcinoma - Medicare Access from HealthWell Foundation. Eligibility is each fund's own rule.
If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.
Swipe to read across
A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.
Every fund we hold for Renal Cell Carcinoma
- OpenRenal Cell Carcinoma - Medicare Access
HealthWell Foundation ·
Award level: not statedInsurance supported: not stated
The page lists the fund as Open. Source page
- Closed or at capacityRenal Cell Cancer
CancerCare ·
Award level: not statedInsurance supported: not stated
The page marks the fund as not currently open for new enrollments (the fund row's own data-statuses attribute reads closed). Source page
- Closed or at capacityRenal Cell Carcinoma
Good Days ·
Award level: not statedInsurance supported: not stated
The page marks the fund as seeking funds for new enrollments (the fund's list item on the page carries the class seeking), so it is not open to applications. Source page
- Closed or at capacityRenal cell carcinoma (RCC)
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $8,000Insurance supported: Medicaid, Medicare, TRICARE
The page lists the fund as Closed. Source page
Drugs whose FDA label names Renal Cell Carcinoma
4 drugs. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 2 have a program (in our assistance finder or on the program's own page) and 0 have a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.
| Drug | What the FDA label says | Manufacturer program | Medicare negotiated price |
|---|---|---|---|
| Inlyta Axitinib Every route for this drug | ... in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Label on openFDA, read 2026-11-10 | Pfizer RxPathways (Pfizer Patient Assistance Program) | not in the CMS negotiated-price file |
| Welireg Belzutifan Every route for this drug | (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring ... Label on openFDA, read 2026-11-10 | Merck Patient Assistance Program | not in the CMS negotiated-price file |
| Lenvima Lenvatinib | Renal Cell Carcinoma (RCC) In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC). Label on openFDA, read 2026-11-10 | not in our assistance finder | selected by CMS for 2028; price not yet published |
| Cabometyx Cabozantinib S-Malate | CABOMETYX is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC). Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
Funds for costs around Renal Cell Carcinoma
These pay for a kind of cost, not a diagnosis. Each is shown with its own status.
Funds for costs around cancer and blood cancer in general: behavioral health (1 open of 2), caregiver support (0 open of 2), clinical trial costs (0 open of 1), home care (1 open of 1), named fund (0 open of 1), pain management (0 open of 1), testing (1 open of 1) and transportation (0 open of 1). Every one is listed, with its source, on the Cancer and blood cancer page.
Related conditions
No broader or more specific condition page for this one.
Group: Cancer and blood cancer. All conditions: the condition index. Fund board for every condition: charitable copay fund status.
What changed
First read on 2026-11-08. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.
This page as data
The same facts as JSON, each fund with its source URL and read date: renal-cell-carcinoma.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.
Questions
Is there an open charitable copay fund for Renal Cell Carcinoma?
As read on 2026-11-08, 1 of the 4 funds we hold for Renal Cell Carcinoma say they are open: Renal Cell Carcinoma - Medicare Access from HealthWell Foundation. Funds open and close, so check the source page before you apply.
Which organizations run funds for Renal Cell Carcinoma?
HealthWell Foundation, CancerCare, Good Days and TotalAssist (Patient Advocate Foundation copay funds). Each fund row on this page links to the organization's own page.
Does an open fund mean I qualify?
No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.
How current is this page?
Statuses are what each fund's own page said on the date we read it (2026-11-08). We do not promise a fund is still in that state today.